Literature DB >> 1984481

Pretreatment with ibuprofen augments circulating tumor necrosis factor-alpha, interleukin-6, and elastase during acute endotoxinemia.

G A Spinas1, D Bloesch, U Keller, W Zimmerli, S Cammisuli.   

Abstract

Plasma levels of tumor necrosis factor-alpha (TNF alpha), interleukin-1 (IL-1), and interleukin-6 (IL-6) were monitored after intravenous administration of Escherichia coli endotoxin with or without ibuprofen pretreatment to healthy volunteers. Intravenous endotoxin (n = 7) resulted in elevated plasma TNF alpha concentrations with maximal levels at 90 min (369 +/- 44 pg/ml, P less than .001 vs. saline controls, n = 7). The rise in TNF-alpha was followed by a rise in plasma IL-6 (27 +/- 12.8 ng/ml), peaking 30-90 min thereafter. Pretreatment with ibuprofen (n = 6) caused a significant augmentation and temporal shift in cytokine elaboration with maximal TNF alpha levels (627 +/- 136 pg/ml) at 120 min and IL-6 peaks (113 +/- 66 ng/ml) at 180 min. In ibuprofen-treated volunteers, the additional increase in TNF alpha was paralleled by increased levels of circulating elastase. In vitro experiments suggest a causal relationship between these events. Thus, the cyclooxygenase inhibitor ibuprofen blunts the clinical response to endotoxin but augments circulating cytokine levels and leukocyte degranulation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1984481     DOI: 10.1093/infdis/163.1.89

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  20 in total

1.  Oral aspirin and ibuprofen increase cytokine-induced synthesis of IL-1 beta and of tumour necrosis factor-alpha ex vivo.

Authors:  S Endres; R E Whitaker; R Ghorbani; S N Meydani; C A Dinarello
Journal:  Immunology       Date:  1996-02       Impact factor: 7.397

Review 2.  Choice of bacteria in animal models of sepsis.

Authors:  A S Cross; S M Opal; J C Sadoff; P Gemski
Journal:  Infect Immun       Date:  1993-07       Impact factor: 3.441

Review 3.  Cytokines as mediators in the regulation of the hypothalamic-pituitary-adrenocortical function.

Authors:  J Fukata; H Imura; K Nakao
Journal:  J Endocrinol Invest       Date:  1994-02       Impact factor: 4.256

4.  Platelets protect from septic shock by inhibiting macrophage-dependent inflammation via the cyclooxygenase 1 signalling pathway.

Authors:  Binggang Xiang; Guoying Zhang; Ling Guo; Xiang-An Li; Andrew J Morris; Alan Daugherty; Sidney W Whiteheart; Susan S Smyth; Zhenyu Li
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

5.  Unopposed interleukin-1 is necessary for increased plasma cytokine and eicosanoid levels to develop in severe sepsis.

Authors:  G J Slotman; J V Quinn; P C Wry; C E Brathwaite; B M Friedman
Journal:  Ann Surg       Date:  1997-07       Impact factor: 12.969

6.  Priming innate immune responses to infection by cyclooxygenase inhibition kills antibiotic-susceptible and -resistant bacteria.

Authors:  Melanie J Stables; Justine Newson; Samir S Ayoub; Jeremy Brown; Catherine J Hyams; Derek W Gilroy
Journal:  Blood       Date:  2010-07-06       Impact factor: 22.113

7.  Effects of in vivo endotoxin infusions on in vitro cellular immune responses in humans.

Authors:  M L Rodrick; N M Moss; J T Grbic; A Revhaug; S T O'Dwyer; H R Michie; D B Gough; D Dubravec; J M Manson; I B Saporoschetz
Journal:  J Clin Immunol       Date:  1992-11       Impact factor: 8.317

Review 8.  Pathophysiology of cancer cachexia.

Authors:  U Keller
Journal:  Support Care Cancer       Date:  1993-11       Impact factor: 3.603

9.  Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxinemia.

Authors:  G A Spinas; U Keller; M Brockhaus
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

10.  Alteration of the physiological responses to indomethacin by endotoxin tolerance in the rat: a possible role for central vasopressin.

Authors:  M F Wilkinson; Q J Pittman
Journal:  J Physiol       Date:  1994-09-15       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.